Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an…

Overview of attention for article published in Trials, October 2021

Altmetric Badge

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 30 Dimensions

Readers on

mendeley: 43 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 2,279 followers.

2/2 #ACR22 JAKi and #JIA associated #uveitis: The JAK-Stat pathway is implicated in uveitis, including JIA-associated uveitis. Efficacy and safety of JAKi currently under study: https://t.co/G2CqmIqrVJ

13 Nov 2022

Reply Repost Favourite

RT @CLUSTER_Tweet: An interesting paper about the first paediatric clinical trial to assess the clinical effectiveness and safety of a JAK…

18 Oct 2021

Reply Repost Favourite

RT @CLUSTER_Tweet: An interesting paper about the first paediatric clinical trial to assess the clinical effectiveness and safety of a JAK…

18 Oct 2021

Reply Repost Favourite

An interesting paper about the first paediatric clinical trial to assess the clinical effectiveness and safety of a JAK inhibitor (baricitinib) in JIA-uveitis or chronic ANA-positive uveitis. https://t.co/zZjvqD4uk3

18 Oct 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.